More should be done to prevent the harmful effects of long-term androgen ablation therapy in prostate cancer

BJU International

Volumn 93, Issue 9, 2004, Pages 1175-1176

  Barrass, B J R ^a   Thurairaja, R ^a   Persad, R A ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; GONADORELIN; PAMIDRONIC ACID; ZOLEDRONIC ACID; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADVANCED CANCER; ANEMIA; BEAM THERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; FRAGILITY FRACTURE; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HIP FRACTURE; HUMAN; LONG TERM CARE; NOTE; ORCHIECTOMY; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; SEXUAL DYSFUNCTION; SIDE EFFECT; ARTICLE; BONE DENSITY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; MALE; PROSTATE TUMOR;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; HUMANS; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS;

EID: 2942717142     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04888.x     Document Type: Note

References (15)

1. Thompson CA, Shanafelt TD, Loprinzi CL. Andropause. symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 2003; 8: 474-87
2. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer. An overview of the randomised trials. Lancet 2000; 355: 1491-8
3. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6
4. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer. Initial results of the Medical Research Council Trial. Br J Urol 1997; 79: 235-46
5. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439-44
6. Oefelein MG, Ricchuiti V, Conrad W et al. Skeletal fracture associated with androgen suppression induced osteoporosis. the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001; 166: 1724-8
7. Oefelein MG, Ricchuiti V, Conrad W et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001; 166: 1724-8
8. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168: 1005-7
9. Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-naive men with prostate carcinoma Cancer 2001; 15: 2238-45
10. Higano CS. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol 2003; 21: 392-8
11. Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Eng J Med 2000; 343: 604-10
12. Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-55
13. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-12
14. Smith MR. Antitumor activity of bisphosphonates. Clin Cancer Res 2003; 15: 5433-4
15. NICE. Improving Outcomes in Urological Cancer - The Manual. National Institute for Clinical Excellence, September 2002